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ABSTRACT
Inhibitors of BRAFV600E kinase are currently under investigations in preclinical 
and clinical studies involving BRAFV600E glioma. Studies demonstrated clinical response 
to such individualized therapy in the majority of patients whereas in some patients 
tumors continue to grow despite treatment. To study resistance mechanisms, 
which include feedback activation of mitogen-activated protein kinase (MAPK) 
signaling in melanoma, we developed a luciferase-modified cell line (2341luc) from 
a BrafV600E mutant and Cdkn2a- deficient murine high-grade glioma, and analyzed 
its molecular responses to BRAFV600E- and MAPK kinase (MEK)-targeted inhibition. 
Immunocompetent, syngeneic FVB/N mice with intracranial grafts of 2341luc were 
tested for effects of BRAFV600E and MEK inhibitor treatments, with bioluminescence 
imaging up to 14-days after start of treatment and survival analysis as primary 
indicators of inhibitor activity. Intracranial injected tumor cells consistently generated 
high-grade glioma-like tumors in syngeneic mice. Intraperitoneal daily delivery of 
BRAFV600E inhibitor dabrafenib only transiently suppressed MAPK signaling, and rather 
increased Akt signaling and failed to extend survival for mice with intracranial 2341luc 
tumor. MEK inhibitor trametinib delivered by oral gavage daily suppressed MAPK 
pathway more effectively and had a more durable anti-growth effect than dabrafenib 
as well as a significant survival benefit. Compared with either agent alone, combined 
BRAFV600E and MEK inhibitor treatment was more effective in reducing tumor growth 
and extending animal subject survival, as corresponding to sustained MAPK pathway 
inhibition. Results derived from the 2341luc engraftment model application have 
clinical implications for the management of BRAFV600E glioma.
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INTRODUCTION
Elevated mitogen-activated protein kinase (MAPK) 
signaling is common in adult and pediatric gliomas. 
Among the gene alterations that promote increased 
MAPK signaling is a single nucleotide substitution in 
BRAF kinase exon 15, which results in expression of 
the constitutively-active BRAFV600E mutant kinase [1]. 
For pediatric glioma, mutation screening studies have 
revealed that BRAFV600E frequencies are highest in grade II 
and III pleomorphic xanthoastrocytoma (PXA) (60-66%) 
[2]. BRAFV600E has also been detected in 18-50% 
of ganglioglioma [3, 4], 5-33% of grade II-IV malignant 
astrocytoma [4–7], and 9% of pilocytic astrocytoma [4, 
5]. We previously reported that five out of seven (71%) 
of BRAFV600E mutant pediatric grade II-IV astrocytoma 
have homozygous deletion of CDKN2A, which encodes 
the p16 tumor suppressor [6]. A subsequent study 
reported that the BRAFV600E mutation and CDKN2A 
deletion are more frequent in pediatric low-grade glioma 
that transform to high-grade malignancy than in non-
transforming tumors [8]. BRAFV600E is less common 
in adult glioma, in which MAPK signaling is most 
often stimulated by gene amplification and mutation of 
upstream receptor tyrosine kinases [9, 10]. Cumulatively, 
the results of mutation screening studies indicate that 
BRAFV600E is important to multiple pediatric glioma types, 
and suggest that this oncogenic alteration cooperates with 
CDKN2A deletion to promote neoplastic transformation 
and tumor malignant progression.
In a previous study, we modeled the combined 
effects of BRAFV600E expression and CDKN2A deficiency 
by crossing the cre-conditional BrafCA [11] and hGFAP-
cre [12] mice to mice lacking Ink4a-Arf [13], a locus 
that contains the murine homolog of CDKN2A. Triple 
transgenic mice expressed BrafV600E in Gfap+ cells 
under control of the endogenous Braf promoter, and 
lacked Cdkn2a expression [14]. These mice died prior to 
developing tumors but cells isolated from the ganglionic 
eminence of BrafCA Ink4a-Arf knock-out mice and 
infected with adenovirus expressing cre recombinase 
(Ad-cre) in culture, became tumorigenic upon intracranial 
injection into SCID mice. We also observed intracranial 
tumor formation by inducing BrafV600E expression and 
Cdkn2a deficiency through injection of Ad-cre into the 
subventricular zone (SVZ) of the lateral ventricle of 
BrafCA mice bred with a cre-conditional knock-out allele 
of Ink4a-Arf (Ink4a-ArfLoxP/LoxP (fl/fl)) [14].
Results from the use of BrafV600E Ink4a-Arf knock-
out murine allografts and BRAFV600E + CDKN2A-deficient 
human glioma xenografts demonstrated the anti-tumor 
activity of PLX4720 [14,15], a tool compound of the 
FDA-approved BRAFV600E-inhibitor vemurafenib. These 
studies helped motivate an active clinical trial for assessing 
vemurafenib in treating children with recurrent BRAFV600E 
glioma (ClinicalTrials.gov Identifier NCT01748149). 
There are early indications that this personalized 
approach benefits some patients with BRAFV600E positive 
ganglioglioma [16,17], recurrent PXA [18] and recurrent 
glioblastoma [19]. Moreover, patients with relapsed or 
refractory high-grade and low-grade BRAFV600E glioma 
have shown radiographic response to treatment with 
BRAFV600E inhibitor dabrafenib in a phase 1 clinical trial. 
In some cases, however, tumors showed progression 
despite dabrafenib treatment, suggesting that some glioma 
have inherent, primary resistance to BRAFV600E targeted 
therapy [20]. The observation of progressive tumor 
growth during treatment is consistent with our more recent 
preclinical studies that showed no significant impact on 
survival rates from PLX4720 monotherapy when treating 
mice with distinct BRAFV600E mutant and CDKN2A 
deficient tumors models (intracranial xenografts from 
pilocytic astrocytoma [21] and glioblastoma [22]).
Here, we present results from the characterization 
and therapeutic testing of a newly developed BrafV600E-
expressing Cdkn2a deficient glioma model, the first to 
involve the use of BrafV600E glioma cells in a syngeneic, 
immunocompetent host. Our study examines the relative 
anti-tumor activity of BRAFV600E vs. MEK targeted 
monotherapy, and of combination therapy using the same 
inhibitors. Compared with the effects of either inhibitor 
alone, combination therapy significantly decreased 
Ki67 positivity, reduced bioluminescence signaling, and 
conferred the most substantial survival benefit to animal 
subjects with lentivirus-luciferase modified, BrafV600E 
expressing Ink4a-Arf knock-out murine allografts. Our 
results demonstrate the utility of this model for testing 
small molecule inhibitors, and should as well, prove useful 
for testing therapies for modulating immune response 
against BRAFV600E mutant glioma.
RESULTS
BrafV600E + Ink4a-Arf deficient 2341luc cells 
produce intracranial tumors in FVB/N mice 
with features characteristic of high-grade 
glioma
To establish a tumor-derived glioma cell line 
carrying the BrafV600E mutation and deficient for Cdkn2a, 
we injected adenovirus expressing cre recombinase 
(Ad-cre) into the corpus callosum of ten week-old, cre-
conditional, FVB/N BrafCA/+ Ink4a/ArfLoxP/LoxP (fl/fl)transgenic 
mice (Figure 1A). Mice consistently developed tumors by 
eight weeks post-injection (Figure 1B). Tumor isolated 
from one such animal (animal number 2341) was used 
in preparing an explant culture that was subsequently 
expanded and modified with firefly luciferase-encoding 
lentivirus (2341luc; Figure 1A). PCR analysis of DNA 
extracted from these cells showed that the BrafV600E 
transgene was expressed (Figure 1C). Deletion of Ink4a-
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Arf, which encodes p16Ink4a and p19Arf, was confirmed by 
quantitative PCR for p16Ink4a (Figure 1D).
To determine whether the 2341 cell line has acquired 
additional genetic changes in selected oncogenes, and in 
particular during modification with luciferase lentivirus, 
we analyzed 2341 cells at initial passage, and following 
lentiviral modification and expansion. Targeted sequencing 
of known oncogenic driver genes, including Akt3, Kras, 
Map2K1, Pik3ca, Pik3r2, Pten, H3f3a and H1h3a showed 
no alteration from wild-type sequence for these genes. 
This result supports earlier observations that expression 
of BrafV600E and deletion of Cdkn2a are sufficient for 
neoplastic transformation (Supplementary Figure S1) [14].
Serial bioluminescence imaging (BLI) of 2341luc 
cells, following intracranial injection of 30,000 cells in 
immunodeficient, Nod scid gamma (NSG) mice, as well 
as in immune competent, syngeneic FVB/N mice, revealed 
progressive increase in luminescence in all injected mice. The 
Figure 1: BrafV600E mutant Ink4a-Arf deleted tumor-derived cells form syngeneic grafts. A. Schematic of 2341luc model 
development. Cells were isolated from a tumor developed in an 18-week-old BrafCA/+ Ink4a/ArfLoxP/LoxP (fl/fl) mouse (animal number 2341) 
that had received adenovirus-cre (Ad:cre) virus injection in the corpus callosum at ten weeks of age. Tumor cells were subsequently 
modified with lentivirus expressing luciferase (2341luc), for injection into syngeneic FVB/N mice. B. Hematoxylin and Eosin staining of 
a tumor developed by injection of Ad:cre as described in A. Arrow points to the location of the tumor and parts of the tumor were excised 
for cell culturing. Scale bar is 1000 μm. C. PCR detection of mutant BrafV600E and BrafCA alleles. Specific primers were used to distinguish 
between the 308 bp band for cre-conditional BrafCA (grey arrow) and the 335 bp band for BrafV600E (black arrow). Panel depicts 2341luc 
cells, which express BrafV600E (BrafVE), control subventricular zone-derived cells with the wild type Braf (BrafWt) or the BrafCA (BrafCA) 
allele. D. QPCR detection of p16Ink4a. Reduced expression of p16Ink4a mRNA was detected by real-time PCR in 2341luc cells (KO; white bar), 
and subventricular zone-derived neurosphere cells homozygous deleted for Ink4a-Arf (KO; grey bar). The mRNA expression levels are 
normalized to expression levels in subventricular zone-derived wild type (Wt) cells, used as control.
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increase in luminescence is more rapid in the NSG animals 
compared with the FVB/N animals (Figure 2A). Median 
symptom-free survival of mice for NSG and FVB/N mice 
was 45 and 58.5 days, respectively (p=0.01; Figure 2B).
H&E staining of sections from resected brains showed 
tumor that was highly cellular, infiltrative, and pleomorphic 
(Figures 2C and 2D). Tumors expressed the astrocyte 
marker Gfap, oligodendrocyte lineage and glioma marker 
Olig2, proliferative marker Ki67, and phosphorylated 
extracellular kinase (phospho-Erk), indicative of active 
MAPK pathway signaling (Figures 2E and 2F).
BrafV600E-expressing Ink4a-Arf knock-out 2341luc 
tumor cells become unresponsive to BRAFV600E-
targeted inhibition
We compared the effects of treating 2341luc cells, in 
vitro, with vemurafenib, which continues to see extensive 
Figure 2: 2341luc syngeneic grafts showed characteristics of high-grade glioma. A. Bioluminescence imaging (BLI) growth 
plots of intracranial tumors established from 2341luc cells in syngeneic, immunecompetent FVB/N and immunecompromised Nod scid 
gamma (NSG) mice, respectively. Values are displayed in arbitrary units (a.u.). The linear plots of log base 10 values indicated that 
exponential increase of bioluminescence was achieved by all tumors, though the rate of increase was slower in FVB/N mice. Standard 
deviations are indicated. B. Kaplan-Meier survival plots for 12 NSG and 10 FVB/N mice, respectively, following intracranial injection of 
30,000 2341luc cells per animal. The median survival post-injection is 58.5 days for FVB/N mice and 45 days for NSG mice (*=p=0.010). 
C, D. H&E-stained tumor tissues showed histopathological features of high-grade glioma, including mitotic figures (C; arrows), 
pleomorphic and hyperchromatic nuclei (C; asterisks) and invading tumor cells (D; arrows). E, F. Immunofluorescence of 2341luc syngeneic 
grafts for astrocyte marker Gfap (green), oligodendrocyte lineage and glioma cell marker Olig2 (red) (E) phospho-Erk (p-Erk; green) and 
proliferation antigen Ki67 (red), is indicative of a high-grade astrocytic tumor (F) White arrows point to double-positive cells. Scale bars 
are 20 μm in C, D and 200 μm in E, F.
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use in treating BRAFV600E mutant cancer, as well as with a 
second FDA-approved inhibitor of BRAFV600E, dabrafenib 
(Db; GSK2118436). Results from inhibitor treatment 
indicated IC50 values of 11.92 nM for Db and 25.61 nM 
for vemurafenib (Figure 3A). A human BRAF wild-type 
pediatric glioma cell line (SF188) exhibited no significant 
response to Db up to concentrations as high as 0.5 µM. 
Vemurafenib concentrations as high as 10 µM only 
reduced cell viability by 40% (Supplementary Figure S2). 
The latter result suggests off-target effects of vemurafenib 
that have been reported by others [27].
We further investigated the 2341luc cell response 
to BRAFV600E inhibitor Db by examining phospho-Erk 
(p-Erk) levels, a commonly used surrogate of MAPK 
pathway activity. Immunoblot results showed p-Erk 
levels decreasing over the first six hours of exposure 
to dabrafenib, with increases evident beyond 24 hours, 
and that ultimately exceeded the phosphorylation levels 
of untreated cells (Figure 3B). Based on our previous 
work [21] as well as the published work of others [28–
31] (Supplementary Figure S3), we analyzed EGFR 
and PI3k-Akt activity in Db-treated 2341luc cells, as 
potential mediators of MAPK signaling rebound. 
Immunoblot results showed increased phospho-Akt 
(p-Akt) from 24 to 48 hours, and increased phospho-
EGFR (p-EGFR) as well as total EGFR at 48 hours 
(Figure 3B).
Db treatment was next examined for anti-
proliferative activity. For this, cells were treated for 48 
hours at Db IC50 concentrations, and then analyzed for 
DNA content by flow cytometry. Db treated cell samples 
showed significantly reduced DNA content relative 
to untreated cells, indicative of reduced proliferation 
(Figure 3C).
Figure 3: Tumor cell response to BRAFV600E inhibitors dabrafenib and vemurafenib in vitro. A. Dose-response-curves 
showing in vitro viability effects of increasing concentrations of dabrafenib (Db; left panel) and vemurafenib (right panel) on 2341luc cells 
(n= 3). B. EGFR, Akt and Erk activities increase in 2341luc cells during treatment with BRAFV600E inhibitor Db. Cells were treated with Db 
at IC50 concentration for up to 48 hours (hrs) and protein was extracted following a 20 min stimulation with EGF (25 ng/ml), and analyzed 
by immunoblotting for phospho-Erk (p-Erk), total Erk (Erk), phospho-Akt (p-Akt), total Akt (Akt), phospho-EGFR (p-EGFR) and total 
EGFR (EGFR). After an initial decrease, p-ERK signal increased from six to 48 hrs, p-Akt signal increased from 24 to 48 hrs and p-EGFR 
as well as EGFR increased at 48 hrs, beyond phosphorylation levels detected before treatment was started. Beta-actin was detected as 
loading control. C. Short-term Db treatment inhibits 2341luc cell proliferation. Cells were treated with IC50 concentrations of Db for 48 hrs, 
incubated with Hoechst dye, and analyzed for DNA content (HO>2), indicative of actively proliferating cells, by flow cytometry. The graph 
shows fold change in proliferative cells (p=0.05).
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Combination therapy is more effective than 
trametinib or dabrafenib monotherapy in 
preventing MAPK activation and inhibiting 
tumor cell proliferation
Clinical results using Db in combination with the 
MEK inhibitor trametinib (Tr) to treat melanoma showed 
improved progression-free survival, compared to either 
inhibitor used as monotherapy [32]. To evaluate the 
potential of this combination therapy for treating BRAFV600E 
high-grade glioma, we first compared single vs. dual 
agent effects on 2341luc cell cultures. After determining 
the IC50 value for Tr (IC50 = 30.5 nM) in 2341luc cells 
(Supplementary Figure S4), we found this concentration to 
be effective at decreasing p-Erk levels in EGF stimulated 
cells (25 ng/ml). This suppressive effect was further 
augmented by combining Tr with Db (Figure 4A). Flow 
cytometry for p-Erk using 2341luc cells, treated for five 
Figure 4: Combined BRAFV600E and MEK inhibition effects on MAPK pathway activity, tumor cell growth and apoptosis. 
A, B. Combined BRAFV600E and MEK inhibition inhibits p-Erk levels more effectivey than MEK inhibition alone. (A) 2341luc cells treated with 
IC50 doses of dabrafenib (Db), trametinib (Tr) or a combination of both (Db+Tr) for four days and stimulated with EGF (25 ng/ml) for 20 min 
before protein extraction were analyzed by immunoblotting for p-Erk and total Erk (Erk). Beta-actin was detected as loading control. P-ERK 
was suppressed by Tr and further suppressed by combination treatment. (B) Flow cytometric quantification of p-Erk levels in 2341luc cells 
treated with Db, Tr or a combination of both (Db+Tr) for five days. Db did not alter p-Erk levels. Tr significantly decreased p-Erk-positive cell 
frequency (**=p=0.0060 for control versus Tr) and combined Db and Tr treatment resulting in further decrease (***=p<0.0001 for Tr versus 
Db + Tr and for control versus Db + Tr; *=p=0.0412 for Db versus Tr). Graph shows percent p-ERK-positive ([%] pERK+) cells normalized 
to control-treated cells = 100%. C. Combination treatment reduces 2341luc cell cycling more effectively than single agent treatment. Cells were 
treated with IC50 concentrations of Db, Tr or a combination of both (Db+Tr) for four days, incubated with Hoechst dye, and analyzed for DNA 
content (HO>2) by flow cytometry. Graph shows fold change in the frequency of cells with a DNA content of HO>2. Tr but not Db decreased 
proliferation significantly (***=p=0.0001 for Tr versus control) and this effect was enhanced by combination treatment (***=p<0.0001 for 
Db+Tr versus control; *=p=0.0149 for Db+Tr versus Tr) (n=3). Graph depicts the fold change of frequency of proliferative cells normalized to 
control-treated cells = 1. D. Single agent and combination treatment increases apoptosis. Cells were treated as in C. and frequency of annexin 
V-positive cells was determined as surrogate for apoptotic cells. Single drug Db and Tr treatment and, more effectively, a combination of both 
significantly increased apoptosis (***=p<0.0001 for Db versus control and Tr versus control; ***=p=0.0002 for Db+Tr versus control). Graph 
depicts fold change of annexin V-positive cell frequency normalized to control-treated cells = 1.
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days with IC50 concentrations of both agents, showed that 
Tr but not Db significantly decreased p-Erk-positive cell 
frequency, with combination treatment resulting in further 
decrease (p<0.001 for Tr versus Db + Tr; Figure 4B).
Single and dual agent treatments were also examined 
for anti-proliferative and pro-apoptotic activities. 
Cells treated for 4 days with IC50 concentrations 
of Db, Tr or a combination, were analyzed by flow 
cytometry for DNA content of HO>2, which is indicative 
for proliferative cells. Db had no significant effect on 
proliferation. In contrast, Tr significantly decreased 
proliferation (p=0.0001 for Tr versus control) and, 
as above, this effect was enhanced by adding Db 
(p=0.0149 for Db + Tr versus Tr; Figure 4C). In 
parallel, cells were analyzed for apoptosis by Annexin 
V staining, with results showing that all treatments 
significantly increased apoptotic cell fractions, with 
the most substantial increases observed for Tr only and 
combination treatments (Figure 4D).
Combination therapy effectively prevents 
MAPK activation, proliferation and increases 
apoptosis in orthotopic tumors
We next examined the effects of treating FVB/N 
mice, bearing syngeneic, orthotopic 2341luc tumors, using 
Db and Tr mono- and combination therapies. Brains with 
tumor, resected at the end of 14-days treatment, were 
stained for p-Erk (Figures 5A and 5B). Single agent Db 
increased p-Erk-positive (p-Erk+) tumor cell frequency 
Figure 5: BRAFV600E and MEK inhibitor mono- and combination therapy effects on MAPK pathway activity, 
proliferation and apoptosis in syngeneic 2341luc grafts. A, B. Combined BRAFV600E and MEK inhibition inhibits p-Erk levels 
more effectively than MEK inhibition alone. A. Immunofluorescence for phospho-Erk (p-Erk) in 2341luc syngeneic grafts treated with 
dimethylsulfoxide (Control), dabrafenib (Db), trametinib (Tr), or a combination of both (Db+Tr), for 14 days starting at day 30 post-
implantation (n=8/group). P-Erk staining is in green. DNA is stained with DAPI and is in blue. Scale bars are 20 μm. B. Quantification 
of p-Erk+ tumor cells in 2341luc syngeneic grafts for each treatment group. P-Erk+ cell frequency was determined using Image J. Db 
monotherapy increased p-Erk+ cell frequency (**=p=0.0075 for Db versus control). Tr monotherapy decreased pErk+ cell frequency, 
compared with Db monotherapy (**p<0.0023 for Tr versus Db), but not with control (p=0.31). Tr in combination with Db significantly 
decreased p-Erk + cell frequency (**=p=0.004 for Db+Tr versus control; ***=p=0.0007 for Db+Tr versus Tr; ***=p<0.0001 for Db+Tr 
versus Db). C–E. Effects of 14-days consecutive inhibitor treatment on proliferation and apoptosis. C. Immunofluorescence images of Ki67 
(top panels) and cleaved caspase-3 (ClC-3; bottom panels) stained tumor tissue from 2341luc syngeneic grafts at day 14 of treatment (n=8/
group). Ki67 and ClC-3 are in green. DNA was stained with DAPI and is shown in blue. Scale bar is 20 μm. D, E. Quantification of Ki67+ 
and ClC-3+ cells in tumors from each treatment group. (Continued )
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Figure 6: BRAFV600E and MEK inhibitor mono- and combination therapy effects on bioluminescence intensity and 
survival in syngeneic BrafV600E expressing Ink4a-Arf knock-out grafts. A. Dabrafenib (Db) and trametinib (Tr) combination 
therapy but not monotherapy shows durable reduction of bioluminescence intensity (BLI). Plots for BLI of 2341luc syngeneic grafts over 14 
day treatments with Db, Tr, or a combination of both (Db+Tr) (n=8/group). Treatment was initiated at day 30 post-implantation of 2341luc 
and BLI was measured on treatment days 3, 7, 10, and 14, and expressed as normalized BLI (fold-change from the start of treatment). 
B. Db and Tr combination therapy but not monotherapy significantly extends survival. Graph shows Kaplan-Meier survival plot of mice 
with 2341luc syngeneic grafts treated with Db or Tr monotherapy or a combination of both, until they developed neurologic symptoms. Db 
monotherapy (median survival = 42 days) failed to extend survival while Tr monotherapy significantly increased survival (median survival 
Tr = 51 days; median survival control = 46 days; p=0.044 for Tr versus control). The combination treatment was most effective in extending 
survival (median survival = 70 days; p=0.049 for Db+Tr versus control).
Figure 5: (Continued ) BRAFV600E and MEK inhibitor mono- and combination therapy effects on MAPK pathway 
activity, proliferation and apoptosis in syngeneic 2341luc grafts. D. Db or Tr monotherapy did not significantly change Ki67+ 
Db or Tr monotherapy did not significantly change Ki67 positivity. Combination treatment significantly decreased Ki67+ cell frequency 
(*=p=0.0339 for Db+Tr versus control; *=p=0.017 for Db+Tr versus Tr). E. Each treatment significantly increased apoptosis compared 
with control (***=p=0.0008 for Db versus control; ***=p<0.0001 for Db+Tr versus control; ***=p<0.0001 for Db+Tr versus Tr).
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(p=0.075), while Tr monotherapy had insignificant effect, 
relative to control (p=0.31). Consistent with the in vitro 
data, Tr in combination with Db significantly decreased 
p-Erk+ cell frequency (p=0.004 for Db+Tr versus control). 
The combination effect was significant in comparison 
with each monotherapy as well (p=0.0007 for Db+Tr 
versus Tr; p<0.0001 for Db+Tr versus Db; Figure 5B). 
We compared differences in p-Akt between treated groups 
at two timepoints during treatment. We observed an 
increase of p-Akt levels after three days of Db treatment 
(Supplementary Figure S5), consistent with the increase 
within 48 hrs of Db treatment in vitro (Figure 3B). P-Akt 
levels increased further within 14 days of Db treatment, 
in association with adaptive resistance. Combined Db 
and Tr therapy prevented the increase of p-Akt levels 
(Supplementary Figures 5A and 5B).
We also examined treatment effects on tumor cell 
proliferation and apoptosis by staining for Ki67 and 
cleaved caspase-3, respectively. Whereas Db monotherapy 
significantly increased Ki67 positivity and Tr monotherapy 
showed no significant effect in relation to control, 
combination therapy significantly decreased Ki67 positive 
cells (p=0.0339 for Db+Tr versus control; p=0.017 for 
Db+Tr versus Tr; Figures 5C and 5D). As treatment effects 
on apoptosis were concerned, all therapies significantly 
increased cleaved caspase-3 positivity, with the most 
substantial increase observed for combined inhibitor 
treatment (Figures 5C and 5E).
Combination therapy effectively inhibits tumor 
cell growth and extends survival
Effects of treatment on lentivirus-luciferase modified, 
syngeneic, orthotopic 2341luc tumors were assessed by 
serial bioluminescence imaging (BLI) of mice treated with 
mono- or combination therapy. The results showed that Db 
and Tr monotherapy reduced BLI for three and seven days, 
respectively, following treatment initiation. Beyond these 
time-points, BLI values increased, despite continuously 
administrating inhibitor daily. In contrast, combination 
therapy inhibited BLI over the entire period of treatment (14 
days; Figure 6A). Consistent with the changes in BLI, Db 
monotherapy provided no survival benefit (median survival 
control = 46 days versus median survival Db = 42 days: p = 
0.253). Tr monotherapy increased survival significantly in 
relation to control group mice (median survival= 51 days; 
p=0.044 for Tr versus control), and combination therapy 
further extended survival (median survival = 70 days; 
p=0.049 for Db + Tr versus control; Figure 6B).
DISCUSSION
The BRAFT1799A point mutation, which results in 
the expression of constitutively active BRAFV600E kinase, 
occurs in many cancers, including gliomas. Array CGH 
and exome sequencing of a population of matched 
pediatric low-grade glioma (PLGG) and secondary high-
grade glioma (sHGG) identified BRAFV600E mutation 
and CDKN2A deletion as the most recurrent alterations 
in sHGG, at 39% and 57% respectively [8]. This study 
determined that BRAFV600E identifies a clinically distinct 
subset of patients whose tumors are more likely to 
undergo malignant progression [8].
Earlier, we assessed whether BRAF activation alone 
would be sufficient for tumor formation, by inducing 
expression of BrafV600E under control of its endogenous 
promoter in Gfap+ cells, by breeding BrafCA/+ hemizygous 
and hGFAP-cre transgenic mice [14]. We found that mice 
only survived for up to three weeks of age without any 
evidence of tumor formation. We concluded that BrafV600E 
expression during development is associated with lethality 
unrelated to glioma formation, and that BrafV600E expression 
alone is insufficient to induce gliomagenesis during the first 
month of age. To test whether BrafV600E cooperates with 
Cdkn2a (Ink4a-Arf  ) deletion to induce glioma formation, we 
injected Ad-cre near the SVZ of adult Braf  CA/+ and Braf  CA/+ 
Ink4a-arf  fl/fl mice, respectively. Combined expression of 
BrafV600E and homozygous deletion of Ink4a-Arf, but not 
expression of BrafV600E alone, induced gliomagenesis. These 
data corroborated that BrafV600E expression cooperates with 
homozygous inactivation of Cdkn2a to generate tumors 
[14]. In the current study, we obtained tumors by injecting 
Ad-cre into the corpus callosum of Braf  CA/+ Ink4a-arf  fl/fl 
mice, which were genetically identical to the mice used in 
the earlier study (Figures 1A and B). From one such tumor 
(#2341), we have developed a syngeneic and orthotopic 
BrafV600E mutant and Cdkn2a deficient engraftment model. 
Our current findings shows that non-SVZ cells expressing 
the BrafV600E mutant and lacking Cdkn2a are capable to give 
rise to transplantable tumors.
Established human BrafV600E GBM lines are capable 
of generating xenografts and are typically kept in serum-
conditions. Prolonged maintenance of cell cultures in the 
presence of serum significantly alters transcriptional and 
genomic cell profiles, in comparison with their parental 
tumor. In contrast, serum-free conditions, such as the 
ones used to maintain the 2341 cells, preserve better the 
expression profiles of the parental tumors [33,34]. The 
2341luc experimental glioma model thus provides a tool 
complementary to the already existing human BRAFV600E 
cell lines.
Histopathology and immunohistochemical 
analyses of 2341luc syngeneic grafts identified high-grade 
astrocytoma-like features and tumor cell phosphorylation 
of Erk, a surrogate for MAPK pathway activation. Tumors 
also co-expressed astrocyte and neural stem cell marker 
Gfap and Olig2, which is rare in normal brain cells, and 
indicates aberrant cell fate specification typical of tumor 
cells (Figures 2C and F) [35].
We found that vemurafenib and Db had IC50 values 
in 2341luc cells in the nanomolar range (Figure 4A), which 
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is consistent with IC50 values of Db in some human 
melanoma cells [36]. With Db being more specific for 
BrafV600E than vemurafenib in 2341luc cells (Supplementary 
Figure S2) and its use in clinical trials for BRAFV600E mutant 
glioma [20], we focused subsequent analyses on effects 
of Db on 2341 cells and grafts. In total, our data support 
transient 2341 cell response to Db, as indicated by effects 
on MAPK pathway activity and cell proliferation (Figures 
4B and 4C). MAPK pathway activity is restored, and in 
addition Akt and EGFR activities are heightened beyond 
six hours of Db treatment, as indicated by phosphoprotein 
immunoblot analyses of Db-treated cells (Figure 3B). 
Moreover, mice carrying 2341 grafts showed elevated p-Akt 
levels after three days of Db treatment, when compared 
with control and combination treatment (Supplementary 
Figure S5). The transient effect of Db on p-Erk levels and 
subsequent increase in p-Akt suggests the ability of 2341 
cells to adapt to BRAFV600E inhibition in a manner similar 
to that seen in melanoma, where mutant BRAF inhibition 
provides strong selective pressure for upregulation of 
MAPK and PI3k-Pten-Akt pathways through epigenetic 
and genetic mechanisms [37].
Moreover, primary resistance or adaptive tumor 
response to BRAF inhibition in melanoma include 
upregulation of receptor tyrosine kinases [30]. A point of 
distinction between glioma and melanoma adaptation to 
BRAFV600E inhibition involves EGFR. We have previously 
shown that human BRAFV600E glioma but not melanoma 
cell lines express high levels of EGFR. Moreover, 
BRAFV600E inhibition of glioma cells with the vemurafenib 
tool compound PLX4720 releases a negative feedback 
loop that is placed on EGFR signaling by BRAFV600E [21]. 
This relationship has also been observed in BRAFV600E 
colorectal cancer [38] and the increase in pEGFR as well 
as total EGFR levels in Db-treated 2341 cells (Figure 3B), 
suggests a similar feedback mechanism in these mouse 
glioma cells (Supplementary Figure S3). Emerging 
clinical data and our preclinical study argue for a similar 
mechanism in glioma where BRAF mutation does not 
always appear to be predictive for responsiveness to 
BRAF inhibitor therapy.
The occurrence of acquired resistance to BRAFV600E 
inhibition in the treatment of various types of cancer 
[39–42] has motivated efforts to develop combination 
therapies to prevent and/or delay tumor adaptation. 
BRAFV600E + MEK inhibitor combination treatment of 
melanoma patients with BRAFV600E mutant tumors have 
shown this to be an effective strategy, as indicated by 
the survival benefit to this patient population [32]. These 
studies have motivated FDA-approval of Tr, a potent 
mitogen-activated protein kinase-1 (MEK)-1/2 inhibitor, 
for use in combination with Db as first-line therapy 
for metastatic melanoma. A further reason to combine 
BRAF and MEK inhibitors in patients is to decrease 
the development of secondary RAS-driven cancers, 
such as squamous cell carcinomas [43] and chronic 
lymphoblastic leukemia [44], that have been reported in 
patients inhibitor treated with BRAF monotherapy. These 
cancers develop due to the paradoxical activation of 
MAPK signaling in BRAF wild-type cells with upstream 
activation of RAS when treated with BRAF inhibitors. 
This MAPK activation is significantly impeded through 
the addition of MEK blockade [45].
Here, our results show that the BRAFV600E inhibitor 
Db has modest effect on intracranial tumor growth 
(Figures 6A and 6B), with rapid and substantial increases 
in MAPK and Akt pathway activities (Figures 5A and 
5B; Supplementary Figure S5). Using this regiment, Db 
reportedly showed remarkable efficacy in reducing tumor 
size in the brains of patients with brain metastasis [41] 
and an intact blood-brain-barrier only partially prevents 
Db from entering the brain [24].
Presumably, as a result of MAPK activity rebound 
and rapidly increasing Akt activity, however, Db 
monotherapy had virtually no effect on animal subject 
survival (Figure 6B). Tr decreased 2341 MAPK pathway 
activity and cell proliferation while increasing apoptosis 
in vitro (Figures 4A-4D), and this translated to a small but 
significant survival benefit for Tr-treated animals bearing 
orthotopic 2341 tumors (Figure 6B). Nonetheless, our 
results shown that 2341 grafts adapt to Tr monotherapy, 
whereas combination treatment delayed acquired 
resistance (Figure 6A). Our data are consistent with those 
obtained by studying human BRAFV600E mutant glioma 
cell lines, which point to re-activation of MAPK pathway 
and increased AKT and EGFR signaling activity as a 
mechanisms of adaptation and resistance to BRAFV600E 
inhibition (Supplementary Figure S3) [21,46]. These 
similarities suggest that our mouse model has clinical 
relevance. Future studies will examine the effects of 
extended combination therapy, including the responses 
of cancer stem cell subpopulations.
The 2341luc model exhibits multiple features of a 
useful preclinical engraftment model, as discussed in 
Oh et al [47], and include in vivo recapitulation of the 
diagnostic histopathology features of a human high-
grade astrocytoma, in vitro tumor cell sustainability 
and amenability to genetic manipulation, engraftment 
consistency, and reproducible as well as predictable 
growth characteristics. As a result of 2341 cells being 
syngeneic to immunocompetent FVB/N mice, we 
anticipate our model as facilitating investigation of 
immunotherapy + small molecule inhibitor treatment of 
BRAFV600E gliomas.
MATERIALS AND METHODS
Isolation of BrafV600E Ink4a-Arf deleted tumor 
cells and cell culturing
Mouse breeding and procedures were conducted 
under an approved Animal Study Protocol according 
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to UCSF Animal Care and Use Committee guidelines. 
Adenovirus-cre (Vector-BioLabs) was injected intracerebral 
using the following coordinates 1 mm anterior, 1 mm lateral 
and 2 mm deep to target the corpus callosum of BrafCA/+ 
Ink4a/ArfLoxP/LoxP (fl/fl)young adult FVB/N mice to induce 
BrafV600E expression under control of the endogenous Braf 
promoter [11], and deletion of p16Ink4a and p19Arf. At eight 
weeks post-injection, we sacrificed mice because they 
exhibited neurologic symptoms and harvested tumor tissue 
and dissociated it with the Neural Dissociation Kit (Miltenyi 
Biotec Inc., San Diego) according to manufacturer’s 
instructions. Primary cells were passaged using Accutase 
(Innovative Cell technologies) in non-adherent conditions at 
37°C under 5% CO2 in Neurobasal-A media (1x B27-A, 1x 
N2, pen/strep, L-glutamine, 5 ng/ml EGF, 5 ng/ml bFGF2 
and 5 ng/ml PDGF).
Genotyping, PCR and targeted sequencing
Genomic PCR to distinguish between BrafCA and 
BrafV600E, was conducted as described [11]. Isolation of 
genomic DNA from cells was performed using 0.5 mg/
ml Proteinase K for one hour followed by precipitation 
with 0.1 M sodium acetate and ethanol extraction. 
Primers were 5’-tgagtatttttgtggcaactgc (forward) 
and 5’-ctctgctgggaaagcggc (reverse) for Braf. Semi-
quantitative PCR for p16Ink4a was conducted as described 
elsewhere [14].
Generation of the 2341luc mouse model, 
bioluminescence imaging and preclinical 
treatment
2341 cells were infected with lentivirus expressing 
luciferase (Genecopoeia LPP-FLUC-Lv105-025) and 
infected cells were selected in the presence of 0.5 µg/
mL puromycin. Adding 500 µg/mL luciferin to 1 x 106 
cells and measuring bioluminescence verified luciferase 
expression. For orthotopic tumor growth 6-week old 
Nod scid gamma (NSG; Jackson Lab) and FVB/N mice 
(Simonsen Laboratories, Gilroy, CA) were implanted with 
30,000 cells/animal and for preclinical testing FVB/N 
mice were injected with up to 4 x 105 2341luc cells/mouse 
as previously described [23]. The protocol was modified 
by suspending cells in 3 µl Matrigel (Corning Life 
Sciences). Using a 10 μl Hamilton gas-tight syringe and a 
stereotactic device (Stoelting; Wood Dale, IL), cells were 
implanted and the needle was withdrawn 120 seconds 
after injection. The burr hole was plugged with sterile 
bone wax and skin closed with Vicryl Rapide (Ethicon). 
For preclinical testing, at 30 days post-implantation, mice 
were randomly assigned to treatment, which consisted of 
vehicle control (DMSO), dabrafenib at 2.5 mg/kg daily 
by intraperitoneal injections [24], trametinib treatment at 
1 mg/kg daily by oral gavage [25] or a combination of 
both for up to 14 days.
Bioluminescence imaging (BLI) was conducted 
twice weekly and signal intensity was quantified as the 
sum of detected photons per second within the region of 
interest using the Living Image software package and 
expressed as normalized BLI (fold-change from the start 
of treatment or original radiance). For survival studies, 
all animals were kept on treatment until reaching the 
major endpoint, which was animal neurological symptom 
free survival. BLI was measured using a Xenogen IVIS 
Spectrum Imaging System.
Alamar Blue cell viability assay and agent 
treatment
Viability assays were conducted as previously 
described [22] with the modification that 1000 cells per 
well were plated and Alamar Blue was added at 24 hours 
and fluorescence was measured 48 hours after plating. 
To assess dose-inhibition curves and IC50 values, we 
used concentrations between 0.1 nM and 0.5 µM of 
vemurafenib, dabrafenib, or trametinib (Selleckchem). 
Each drug was tested alone or in combination in three 
replicates in three independent experiments. DMSO-
treated cell values were considered as 100% viability. The 
IC50 concentration was used to treat cells for four or five 
days at 48 hours intervals with dabrafenib, trametinib, or 
both before flow cytometry and immunoblotting.
Flow cytometry
Treated 2341 cells were fixed in 2% 
paraformaldehyde, permeabilized in 100% ice-cold 
methanol and stained with rabbit p-ERK antibody (Cell 
Signaling #4377S) and donkey anti-rabbit IgG-647 
(Jackson Labs #711-136-152). Cell cycle analyses were 
conducted by treating cells with Hoechst 33342 at a final 
concentration of 2 ng/ml and DNA content (2n versus 
4 n) was determined as described [26]. Analyses were 
conducted using the FACS ARIA II (BD Biosciences). 
Annexin V staining was performed on unfixed cells 
using the FITC Apoptosis detection Kit according to 
manufacturer instructions (BD Cell Analysis).
Immunoblotting
Treated 2341 cells were stimulated with EGF 
(20ng/ml) for 20 min prior to protein extraction which 
was performed using cell lysis buffer (Cell Signaling) 
supplemented with proteinase and phosSTOP phosphatase 
inhibitor cocktail (Roche). Proteins were separated 
by SDS-PAGE and transferred onto polyvinylidene 
difluoride membranes, which were then probed with 
primary antibodies, followed by horseradish peroxidase-
conjugated secondary antibody, and visualized by ECL 
(GE Healthcare). Antibodies specific for p-EGFR 
(Tyr1068), p-Akt (Ser473), total Akt, p-ERK, and 
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beta-actin were from Cell Signaling Technology. Total 
EGFR and total ERK antibodies were from Santa Cruz 
Biotechnology, Inc.
Immunofluorescence (IF)
Tissue sections from 4% paraformaldehyde (PFA)-
perfused mouse brains were cut and stained as 10 μm 
sections. Sections were post-fixed with 4% PFA for 10 
minutes, washed and blocked with PBS-0.1% triton-5% 
normal donkey serum. All sections were incubated with 
primary antibody and secondary antibody, as well as 
streptavidin conjugate as described [22].
The following antibodies and streptavidin conjugates 
were used: Rabbit anti-pERK (Cell Signaling Technology, 
dilution 1:200), rabbit anti-p-Akt (Ser473, D9E, Cell 
Signaling Technology, Inc, dilution 1:200), rabbit anti-
Gfap (DAKO, dilution 1:400), goat anti-Olig2 (R&D, 
dilution 1:500), goat anti-Ki67 (Santa Cruz, dilution 
1:200), rabbit anti-Ki67 (Cell Signaling Technology, 
dilution 1:200) and rabbit anti-cleaved caspase-3 (Cell 
Signaling Technology, dilution 1:400). The secondary 
antibodies used were donkey IgG-fluorescence conjugates 
(Jackson ImmunoResearch, dilution 1:400). Images were 
obtained using a Zeiss AxioImager M1 microscope with 
Zen 2 software (Carl Zeiss microcopy 2011). Images were 
also acquired at the 6D high throughput epifluorescent 
system (Nikon Imaging Center at UCSF) The presence of 
tumors was confirmed by DAPI staining and H&E staining 
of consecutive sections.
Statistics and analysis
Statistical analyses were conducted as indicated 
in the figure legends using GraphPad Prism 5.0 and 
Microsoft Excel. For determination of the IC50s in vitro 
drug efficacy studies non-linear regression analyses were 
utilized. A two-tailed paired t-test was conducted to 
analyze for significant differences between two treatment 
groups in flow cytometry experiments assessing DNA 
content and annexin V. An unpaired t-test was conducted 
to analyze differences between two treatment groups in 
flow cytometry experiments detecting p-ERK. One-way 
ANOVA was used to analyze differences between three 
or more groups. For Kaplan–Meier survival rate analyses, 
the number of surviving mice in the three groups of 
animals were recorded daily after 2341luc implantation. 
The data were subjected to Log-rank test in order to 
determine if significant differences existed in survival 
between the experimental groups. For statistical tests 
*=p<0.05, **=p<0.01, ***=p<0.001.
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